Adaptions and Resiliency to Multi-Stressor OpeRations

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2026

Conditions
Musculoskeletal InjuryHypogonadism
Interventions
DRUG

Goserelin 3.6 MG

Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH). GnRH agonists induce a transient increase in sex hormone concentrations, but subsequently inhibit gonadotropin secretion and the production of testosterone in men and estrogen in women. An equilibration period will occur to allow steroid concentrations to reduce.

OTHER

Multi-Stressor Training

A 4-week physical training program that mimics military training.

DRUG

Testosterone gel (AndroGel 5g)

Male subjects will be randomly assigned to receive a topical testosterone gel (5g dose).

DRUG

Testosterone gel (AndroGel 1.25g)

Male subjects will be randomly assigned to receive a topical testosterone gel (1.25g dose).

DRUG

Estradiol / Levonorgestrel Transdermal System [Climara Pro]

Female subjects will be randomly assigned to receive a estrogen/ progesterone patch.

DRUG

Placebo Patch

Female subjects will be randomly assigned to receive a placebo patch identical to the Climara Pro patch.

Trial Locations (1)

15203

RECRUITING

Neuromuscular Research Laboratory, Pittsburgh

All Listed Sponsors
collaborator

U.S. Army Medical Research and Development Command

FED

lead

Bradley Nindl

OTHER